SCHEMBL490565

SCHEMBL490565

CCCCCC(CCCCCCCCCCCCOCCO)OC(CCCCC)CCCCCCCCCCCCOCCO

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
THRB P10828 1/20 0.68
MAPT P10636 1/20 0.68
TSHR P16473 1/20 0.57
USP2 O75604 2/20 0.46
LMNA P02545 2/20 0.41
CES1 P23141 1/20 0.41
CES2 O00748 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SLCO1B3 Q9NPD5 1/20 0.40
SLCO1B1 Q9Y6L6 1/20 0.40
LPAR1 Q92633 6/20 0.39
LPAR3 Q9UBY5 6/20 0.39
LPAR2 Q9HBW0 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8772504 1.00 HTT (0.68) HTTMEN1KMT2ATHRBMAPT
SCHEMBL491059 0.96 MEN1 (0.62) HTTMEN1KMT2ATHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL5146482 0.96 MEN1 (0.61) HTTMEN1KMT2ATHRBMAPT
Triethylene Glycol SCHEMBL26983266 0.94 MEN1 (0.64) HTTMEN1KMT2ATHRBMAPT
Tetraethylene Glycol SCHEMBL5142076 0.94 MEN1 (0.64) HTTMEN1KMT2ATHRBMAPT
Di(Hydroxyethyl)Ether SCHEMBL5142109 0.94 MEN1 (0.59) HTTMEN1KMT2ATHRBMAPT
Triethylene Glycol SCHEMBL28536690 0.94 MEN1 (0.64) HTTMEN1KMT2ATHRBMAPT
Triethylene Glycol SCHEMBL5143692 0.94 MEN1 (0.64) HTTMEN1KMT2ATHRBMAPT
Tetraethylene Glycol SCHEMBL5141969 0.93 MEN1 (0.62) HTTMEN1KMT2ATHRBMAPT
SCHEMBL490669 0.93 MEN1 (0.57) HTTMEN1KMT2ATHRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020216641-A1 A HAIR WAX COMPOSITION BEIERSDORF AG (DE) 2020-10-29 WO claimed
US-11110121-B2 Compositions comprising hydrogen peroxide or hydrogen peroxide donor substances CLARIANT INTERNATIONAL LTD. (CH) 2021-09-07 US disclosed
US-10888719-B2 Active substance combination of creatine and/or creatinine and phenoxyethanol BEIERSDORF AG (DE) 2021-01-12 US disclosed
US-10682534-B2 Cosmetic preparations containing creatine and/or creatinine and organic thickeners BEIERSDORF, AG (DE) 2020-06-16 US disclosed
US-10406135-B2 Compositions containing isosorbide monoester and alcohols that contain at least one aromatic group CLARIANT INTERNATIONAL LTD. (CH) 2019-09-10 US disclosed
US-9834635-B2 Polymers based on arcrylic, methacrylic or ethacrylic amidoalkyl sulfonic acid or salts and carboxyalky acrylate, methacrylate or ethacrylate or oligomers of said carboxy compounds CLARIANT INTERNATIONAL LTD. (CH) 2017-12-05 US disclosed
US-9693973-B2 Active substance combination of licochalcone A and phenoxyethanol BEIERSDORF AG (DE) 2017-07-04 US disclosed
US-9526687-B2 Polymers based on sulfonic acids, amides and special cross-linking agents CLARIANT INTERNATIONAL LTD. (CH) 2016-12-27 US disclosed
US-9295626-B2 Compositions comprising isosorbide monoester and N-hydroxypyridones CLARIANT INTERNATIONAL LTD. (CH) 2016-03-29 US disclosed
US-9237999-B2 Cosmetic or pharmaceutical composition comprising modified polyorganosiloxanes CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2016-01-19 US disclosed
US-20040037797-A1 Water-in-oil emulsions containing one or more ammonium acryloylodimethyltaurate/vinylpyrrolidone copolymers BEIERSDORF AG 2004-02-26 US disclosed
US-6620420-B2 Cosmetic or dermatological application BEIERSDORF AG (DE) 2003-09-16 US disclosed
US-20030147928-A1 Water, oil in water emulsifiers, optionally coemulsifiers, oil phase(s), polidocanol and an essential oil; saturated cloth; immediate and long-lasting effect BEIERSDORF AG 2003-08-07 US disclosed
US-20030091605-A1 Use of alpha-lipoic acid for producing cosmetic or dermatological preparations for regenerating stressed skin, in particular aged skin BEIERSDORF AG 2003-05-15 US disclosed
US-20030012801-A1 Active ingredient combinations of surface-active citric esters and inclusion compounds of cyclodextrins and retinoids, and cosmetic and dermatological preparations containing such mixtures BEIERSDORF AG 2003-01-16 US disclosed
US-20020176832-A1 O/W emulsions containing one or more ammonium acryloyldimethyltaurate/vinylpyrrolidone copolymers CLARIANT INTERNATIONAL LTD. (CH) 2002-11-28 US disclosed
US-20020155076-A1 Gel creams in the form of O/W emulsions containing one or more ammonium acryloyldimethyltaurate/vinylpyrrolidone copolymers CLARIANT INTERNATIONAL LTD. (CH) 2002-10-24 US disclosed
US-20020119114-A1 Active ingredient combinations of surface-active citric esters and alpha-lipoic acid, and cosmetic and dermatological preparations containing such mixtures BEIERSDORF AKTIENGESELLSCHAFT 2002-08-29 US disclosed
US-6436414-B1 Active ingredient combinations or adducts of biotin and/or biotin derivatives and cyclodextrins and use of such active ingredient combinations in cosmetic preparations BEIERSDORF AG (DE) 2002-08-20 US disclosed
US-20020045596-A1 Active ingredient combinations or adducts of cyclodextrins and at least one quinone and/or at least one hydroquinone and use of such active ingredient combinations in cosmetic preparations BEIERSDORF AG (DE) 2002-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045596-A1 Active ingredient combinations or adducts of cyclodextrins and at least one quinone and/or at least one hydroquinone and use of such active ingredient combinations in cosmetic preparations NQO1, RECQL, KEAP1 HTT 235/4885MEN1 2565/4885KMT2A 3530/4885
US-10888719-B2 Active substance combination of creatine and/or creatinine and phenoxyethanol REN, CKMT1A; CKMT1B, CRAT HTT 2638/4885MEN1 4090/4885KMT2A 951/4885
US-11110121-B2 Compositions comprising hydrogen peroxide or hydrogen peroxide donor substances GPX4, LPO, CAT HTT 47/4885MEN1 3224/4885KMT2A 4648/4885
US-20030012801-A1 Active ingredient combinations of surface-active citric esters and inclusion compounds of cyclodextrins and retinoids, and cosmetic and dermatological preparations containing such mixtures ALDH1A2, GAA, GCDH HTT 3635/4885MEN1 3273/4885KMT2A 4662/4885
US-20020176832-A1 O/W emulsions containing one or more ammonium acryloyldimethyltaurate/vinylpyrrolidone copolymers AGPAT2, PHOSPHO1, MBOAT1 HTT 595/4885MEN1 4169/4885KMT2A 743/4885
US-20020155076-A1 Gel creams in the form of O/W emulsions containing one or more ammonium acryloyldimethyltaurate/vinylpyrrolidone copolymers AGPAT2, ACMSD, POLR1C HTT 304/4885MEN1 4477/4885KMT2A 1076/4885
US-20020119114-A1 Active ingredient combinations of surface-active citric esters and alpha-lipoic acid, and cosmetic and dermatological preparations containing such mixtures LIPA, GLA, DEGS1 HTT 2257/4885MEN1 1433/4885KMT2A 2016/4885
US-20030091605-A1 Use of alpha-lipoic acid for producing cosmetic or dermatological preparations for regenerating stressed skin, in particular aged skin CUTA, LIPA, LPO HTT 747/4885MEN1 4447/4885KMT2A 4069/4885
US-10682534-B2 Cosmetic preparations containing creatine and/or creatinine and organic thickeners CKMT1A; CKMT1B, OTC, CRAT HTT 386/4885MEN1 3729/4885KMT2A 1333/4885
US-10406135-B2 Compositions containing isosorbide monoester and alcohols that contain at least one aromatic group ADH5, ADH1A, ADH1C HTT 4773/4885MEN1 3537/4885KMT2A 4657/4885
US-20030147928-A1 Water, oil in water emulsifiers, optionally coemulsifiers, oil phase(s), polidocanol and an essential oil; saturated cloth; immediate and long-lasting effect POLD1, POLD3, POLI HTT 3193/4885MEN1 4540/4885KMT2A 1719/4885
US-20040037797-A1 Water-in-oil emulsions containing one or more ammonium acryloylodimethyltaurate/vinylpyrrolidone copolymers PHOSPHO1, AGPAT2, AGPAT5 HTT 247/4885MEN1 3181/4885KMT2A 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.